×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu
Mark Story

Mark Story

A former editor, columnist, and chief reporter on business and financial publications across NZ, Australia, Hong Kong and the US, Mark operates Prime Strategy Media. He divides his time between share market commentary and analysis, B2B, financial, mainstream media, and high level content and strategy for financial institutions.

Commodities / Mark Story / Markets

Australia Pivots to ‘First-Call’ Global Mineral Supplier Status

April 9, 2021April 9, 2021 - by Mark Story

In light of the vital role mining plays within the economy, the government recently detailed plans for Australia to become a leading global supplier of resources services over the next decade.

Read More
Markets / Shares

Aristocrat Signals Bullish Rebound

April 7, 2021 - by Mark Story

Brokers have walked away from Aristocrat’s recent investor briefing incrementally more confident the company will emerge post-covid in a stronger competitive position

Read More
Mark Story / Markets

Share Purchases and the Company You Keep

March 26, 2021March 26, 2021 - by Mark Story

When small-cap promo sites morph into fund managers, it’s time to scrutinise which stocks are being covered, why, and who is bringing them to your attention.

Read More
Mark Story / Markets

Investing vs Gambling: Do you know the difference?

March 19, 2021March 19, 2021 - by Mark Story

Confusion between investing and gambling severely compromises your ability to accumulate long-term wealth: Do you know the difference?

Read More
Economics / Fixed Interest / Interest Rates / Markets

Have Bonds Moved Too Fast, Too Far?

March 16, 2021 - by Mark Story

While bonds yields have risen on higher inflationary expectations, driven by higher commodity prices and expectations surrounding large US fiscal stimulus, the big unknown is what will happen next?

Read More
Markets

Aged Care Sector: Poised

March 16, 2021 - by Mark Story

Despite uncertainty following the Royal Commission, a more immediate funding response is expected to find its way to the listed providers, and likely boost FY21 earnings.

Read More
Commodities / Mark Story / Markets

Crude Shock Awaits the Commodity We Love to Hate

March 12, 2021March 15, 2021 - by Mark Story

Dwindling appetite for exploration, a pandemic-driven drop in global demand, and US shale operators seemingly running out of puff, have all coalesced to make the ‘perfect storm’ of higher prices and limited supply that is brewing for OPEC.

Read More
Commodities / Markets

Material Matters: Nickel, Bulks, Oil, Gold

March 8, 2021March 8, 2021 - by Mark Story

Tsingshan’s battery contract triggers nickel over-supply concern. Major steel production cuts mooted. Is an oil price consolidation period due? Bulks well supported, demand cooling for base metals. Gold loses appeal.

Read More
Mark Story / Markets / Technology

Pending Co2 Footprint for EVs Puts Mineral Suppliers on Notice

March 5, 2021March 5, 2021 - by Mark Story

A decision by the EU last year to recalibrate the ecosystem around the manufacturing of electric vehicles (EVs), has serious implications for suppliers of minerals to battery and EV producers globally.

Read More
Markets / Shares

Service Stream: Margin Pressure Versus NBN Upside

March 3, 2021 - by Mark Story

While Service Stream has indicated its second half would continue to be weak, material wins under NBN Co’s upgrade program could be an important swing factor.

Read More
Biotechnology / Markets / Shares / Technology / Video

Genetic Signatures Leverages New Screening Targets to EU and US Markets

March 3, 2021March 3, 2021 - by Mark Story

GeneticSignatures (ASX: GSS) a specialist molecular diagnostics (MDx) company, plans to leverage its existing suite of real-time screening products into an expanding customer base.

Read More
Biotechnology / Markets / Shares / Video

Kazia Licenses Ovarian Cancer Drug to Swedish Pharmaceutical Company

March 1, 2021March 1, 2021 - by Mark Story

Australian oncology-focused company, Kazia Therapeutics has just announced a license agreement with Swedish speciality pharmaceutical company Oasmia Pharmaceutical for its ovarian cancer drug Cantrixil.

Read More
Commodities / Mark Story / Markets

Fuelling a Closer Look at Hydrogen

February 26, 2021February 26, 2021 - by Mark Story

Taking a ground-floor position in listed hydrogen stocks could return in spades over time. Mark Story explains why.

Read More

Recently Added

  • BSL – Credit Suisse rates the stock as Outperform
  • URW – Citi rates the stock as Sell
  • AWC – Credit Suisse rates the stock as Outperform
  • BPT – Morgans rates the stock as Add
  • Morning Report: US sharemarkets climbed to all-time highs on Friday
  • Hidden Gems Webinar Recap – PFG, EXL, MX1, BRU
  • Prime Financial Group (ASX: PFG) – Hidden Gems Webinar Presentation
  • Micro-X (ASX: MX1) – Hidden Gems Webinar Presentation

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

Do Two A+ Deals Foreshadow THE DEAL?

Licensing deals are the life blood of small pharmaceutical companies, representing their exit from the development of a molecule, often in a staged manner, and a coalescing of the value they have added to a compound. Kazia Therapeutics has done two licensing deals in the space of a month, something unique for an Australian company. In this report, we look at those deals, assess their quality and look at other takeaways they provide.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Plane.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Cup.

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Car.

DOWNLOAD RESEARCH REPORT

The EV Megatrend – Responsibly sourced lithium the “new oil”

Lake Resources (LKE.AX) aims to become a major global producer of high quality battery grade lithium carbonate. It holds 100% equity in four significant Argentinian brine assets situated in the Lithium Triangle. LKE is using disruptive lithium extraction technology to produce lithium for sales into the US, Europe and Asia. With its clean tech partner Lilac Solutions, LKE is moving fast to bring a low carbon, low water, low waste, no acid products, light footprint, low-cost and high value project to market.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Plane.